SCI
RARE icon

S&CO Inc’s Ultragenyx Pharmaceutical RARE Stock Holding History

S&CO Inc’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,255
Closed -$529K – 228
2026
Q1 		$529K Hold
25,255
– – 0.03% 165
2025
Q4 		$580K Hold
25,255
– – 0.04% 167
2025
Q3 		$759K Hold
25,255
– – 0.05% 161
2025
Q2 		$918K Buy
25,255
+5,000
+25% +$180K 0.06% 146
2025
Q1 		$733K Hold
20,255
– – 0.05% 159
2024
Q4 		$852K Hold
20,255
– – 0.06% 144
2024
Q3 		$1.13M Hold
20,255
– – 0.07% 135
2024
Q2 		$832K Buy
+20,255
New +$865K 0.06% 149

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

S&CO Inc's RARE Position: Q2 2026 in Review

S&CO Inc sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 25,255 shares — an estimated $529K sold.

S&CO Inc first reported a position in RARE in Q2 2024 and held it in 8 quarters. The position peaked at $1.13M in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • S&CO Inc reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • S&CO Inc sold 25,255 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $529K.
  • S&CO Inc first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and held it in 8 quarters.
  • S&CO Inc's Ultragenyx Pharmaceutical position peaked at $1.13M in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on S&CO Inc's 13F filing for Q2 2026, filed 6 Aug 2026.